These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34285278)

  • 61. Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.
    Kwiatkowska E; Skasko E; Niwinska A; Wojciechowska-Lacka A; Rachtan J; Molong L; Nowakowska D; Konopka B; Janiec-Jankowska A; Paszko Z; Steffen J
    Neoplasma; 2006; 53(4):305-8. PubMed ID: 16830057
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association of rare MSH6 variants with familial breast cancer.
    Wasielewski M; Riaz M; Vermeulen J; van den Ouweland A; Labrijn-Marks I; Olmer R; van der Spaa L; Klijn JG; Meijers-Heijboer H; Dooijes D; Schutte M
    Breast Cancer Res Treat; 2010 Sep; 123(2):315-20. PubMed ID: 19924528
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CHEK2 variant I157T may be associated with increased breast cancer risk.
    Kilpivaara O; Vahteristo P; Falck J; Syrjäkoski K; Eerola H; Easton D; Bartkova J; Lukas J; Heikkilä P; Aittomäki K; Holli K; Blomqvist C; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2004 Sep; 111(4):543-7. PubMed ID: 15239132
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 66. No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors.
    de Jong MM; Nolte IM; Te Meerman GJ; van der Graaf WT; Oosterom E; Bruinenberg M; Steege Gv; Oosterwijk JC; van der Hout AH; Boezen HM; Schaapveld M; Kleibeuker JH; de Vries EG
    Eur J Cancer; 2005 Aug; 41(12):1819-23. PubMed ID: 16043347
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.
    Sodha N; Bullock S; Taylor R; Mitchell G; Guertl-Lackner B; Williams RD; Bevan S; Bishop K; McGuire S; Houlston RS; Eeles RA
    Br J Cancer; 2002 Dec; 87(12):1445-8. PubMed ID: 12454775
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
    Osorio A; Rodríguez-López R; Díez O; de la Hoya M; Ignacio Martínez J; Vega A; Esteban-Cardeñosa E; Alonso C; Caldés T; Benítez J
    Int J Cancer; 2004 Jan; 108(1):54-6. PubMed ID: 14618615
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
    Weischer M; Nordestgaard BG; Pharoah P; Bolla MK; Nevanlinna H; Van't Veer LJ; Garcia-Closas M; Hopper JL; Hall P; Andrulis IL; Devilee P; Fasching PA; Anton-Culver H; Lambrechts D; Hooning M; Cox A; Giles GG; Burwinkel B; Lindblom A; Couch FJ; Mannermaa A; Grenaker Alnæs G; John EM; Dörk T; Flyger H; Dunning AM; Wang Q; Muranen TA; van Hien R; Figueroa J; Southey MC; Czene K; Knight JA; Tollenaar RA; Beckmann MW; Ziogas A; Christiaens MR; Collée JM; Reed MW; Severi G; Marme F; Margolin S; Olson JE; Kosma VM; Kristensen VN; Miron A; Bogdanova N; Shah M; Blomqvist C; Broeks A; Sherman M; Phillips KA; Li J; Liu J; Glendon G; Seynaeve C; Ekici AB; Leunen K; Kriege M; Cross SS; Baglietto L; Sohn C; Wang X; Kataja V; Børresen-Dale AL; Meyer A; Easton DF; Schmidt MK; Bojesen SE
    J Clin Oncol; 2012 Dec; 30(35):4308-16. PubMed ID: 23109706
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increased risk of breast cancer associated with CHEK2*1100delC.
    Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
    J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
    Wang N; Ding H; Liu C; Li X; Wei L; Yu J; Liu M; Ying M; Gao W; Jiang H; Wang Y
    Oncogene; 2015 Oct; 34(40):5198-205. PubMed ID: 25619829
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
    Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
    Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
    Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
    Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CHEK2 mutations and the risk of papillary thyroid cancer.
    Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
    Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CHEK2 1100delC and male breast cancer in the Netherlands.
    Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
    Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.
    Huszno J; Budryk M; Kołosza Z; Tęcza K; Pamuła Piłat J; Nowara E; Grzybowska E
    Oncology; 2016; 90(4):193-8. PubMed ID: 26991782
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The CHEK2 1100delC variant in Swedish colorectal cancer.
    Djureinovic T; Lindblom A; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Eiberg H; Bisgaard ML
    Anticancer Res; 2006; 26(6C):4885-8. PubMed ID: 17214356
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue.
    Ni VI; Ivantsov AO; Kotkova MA; Baskina SV; Ponomareva EV; Orlova RV; Topuzov EE; Kryukov KK; Shelekhova KV; Aleksakhina SN; Sokolenko AP; Imyanitov EN
    Fam Cancer; 2021 Jan; 20(1):49-53. PubMed ID: 32451744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.